Stifel Resumes Prometheus Biosciences Inc (RXDX) at Buy

November 12, 2021 5:58 AM EST
Get Alerts RXDX Hot Sheet
Price: $28.82 -3.55%

Rating Summary:
    6 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 9 | Down: 11 | New: 61
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Stifel analyst Annabel Samimy resumes coverage on Prometheus Biosciences Inc (NASDAQ: RXDX) with a Buy rating and a price target of $45.00.

The analyst commented, "We resume coverage of Prometheus Biosciences (RXDX) with a Buy rating and $45TP. Capitalizing on the expansion of precision medicine, RXDX is the first to apply development successes seen in oncology/CNS/cardiology to gastrointestinal/GI diseases, with lead program PRA023—an anti-TL1A antibody for inflammatory bowel disease (IBD). Uniquely, RXDX has exclusive access to an extensive GI database that will allow it to screen patients for enrollment, serving to shorten development timelines and further enrich trial populations for enhanced efficacy. Combined with target validation from PFE’s own anti-TL1A program, we think RXDX has designed a robust program that will accelerate clinical development with what could be a best-in-class approach, with a companion diagnostic to assist in appropriate patient identification—attractive for physicians and payers alike. Lastly, RXDX is applying precision medicine to identify additional conditions, broadening personalized medicine across autoimmune disease, with the next indication soon to emerge."

For an analyst ratings summary and ratings history on Prometheus Biosciences Inc click here. For more ratings news on Prometheus Biosciences Inc click here.

Shares of Prometheus Biosciences Inc closed at $37.00 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities